Neo-adjuvant and adjuvant chemotherapy of gastric cancer

Neo-adjuvant and adjuvant chemotherapy of gastric cancer.

Gastric cancer is still a major health problem and a leading cause of cancer mortality despite a worldwide decline in incidence. Surgery is the primary curative treatment of locoregional gastric cancer. In Western countries, however, at the time of resection, most patients are expected to have regional lymph node involvement with poor prognostic implications. To improve these results, different...

Neo-adjuvant and adjuvant chemotherapy in bladder cancer.

Transitional cell carcinoma of the bladder represents the second most common genitourinary malignancy [1]; the clinical approach to muscle-invasive disease has been modified in the last decade, considering the important role of multidisciplinary team, including surgeon, oncologist and radiotherapist. In fact, despite relevant progress in surgical management of these patients, the global prognos...

[Neo-adjuvant chemotherapy for breast cancer].

OBJECTIVE To study the value and indications of a neo-adjuvant chemotherapy for breast cancers. METHODS Forty-three breast cancer patients were given the NF neo-adjuvant chemotherapy (Navelbine 25 mg/m2 and 5-Fu 500 mg/m2) for 3 cycles before the operation. Epirubicin (EPI 40 mg/m2) was added in patients with locally advanced lesions. G-CSF 75 micrograms subcutaneous injection was used to inc...

The neo - adjuvant , surgical and adjuvant treatment of gastric adenocarcinoma

Adjuvant chemotherapy of gastric cancer: which regimens?

Gastric cancer is still a major health problem and a leading cause of cancer mortality despite a worldwide decline in incidence. Surgical resection with curative potential is the only treatment modality of scientific proven effectiveness. Many phase III trials of adjuvant therapy have been conducted, however, postoperative treatment modalities have not proven to be superior to pos-surgical obse...